(Q50479057)

14 March 2018

title

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. (English)

1 reference

14 March 2018

main subject

phase II clinical trial

0 references

1

Eduardo Tolosa

1 reference

14 March 2018

5

Andrew Lees

1 reference

14 March 2018

2

Irene Litvan

1 reference

ORCID Public Data File 2021

14 March 2018

1 reference

author name string

Günter U Höglinger

3

1 reference

14 March 2018

David Burn

4

1 reference

14 March 2018

María V Andrés

6

1 reference

14 March 2018

Belén Gómez-Carrillo

7

1 reference

14 March 2018

Teresa León

8

1 reference

14 March 2018

Teodoro Del Ser

9

1 reference

14 March 2018

TAUROS Investigators

10

1 reference

14 March 2018

language of work or name

English

0 references

publication date

14 February 2014

1 reference

14 March 2018

published in

Movement Disorders

1 reference

14 March 2018

volume

29

1 reference

14 March 2018

issue

4

1 reference

14 March 2018

page(s)

470-478

1 reference

14 March 2018

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

cites work

1 reference

Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies

21 January 2018

1 reference

The glamour and gloom of glycogen synthase kinase-3

21 January 2018

1 reference

Pharmacological inhibitors of glycogen synthase kinase 3.

21 January 2018

1 reference

Progressive supranuclear palsy: where are we now?

21 January 2018

1 reference

Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes

21 January 2018

1 reference

Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis

21 January 2018

1 reference

CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium

21 January 2018

1 reference

GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity.

21 January 2018

1 reference

Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β.

21 January 2018

1 reference

Rational therapeutic approaches to progressive supranuclear palsy

21 January 2018

1 reference

Glycogen synthase kinase 3: a drug target for CNS therapies

21 January 2018

1 reference

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

21 January 2018

1 reference

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib

21 January 2018

1 reference

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

21 January 2018

1 reference

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease

21 January 2018

1 reference

NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders.

21 January 2018

1 reference

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

21 January 2018

1 reference

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

21 January 2018

1 reference

A new rating scale for age-related white matter changes applicable to MRI and CT.

21 January 2018

1 reference

A clinical rating scale for progressive supranuclear palsy.

21 January 2018

1 reference

The timed "Up & Go": a test of basic functional mobility for frail elderly persons

21 January 2018

1 reference

The FAB: a Frontal Assessment Battery at bedside.

21 January 2018

1 reference

Reliability, validity, and clinical correlates of apathy in Parkinson's disease

21 January 2018

1 reference

EQ-5D: a measure of health status from the EuroQol Group

21 January 2018

1 reference

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

21 January 2018

1 reference

Donepezil in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

21 January 2018

1 reference

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

21 January 2018

1 reference

Idazoxan treatment in progressive supranuclear palsy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.25824

1 reference

14 March 2018

PubMed ID

24532007

1 reference

14 March 2018